$0.00
(Market cap
$10 Mln
Recently Viewed
Clear AllMarket cap
$10 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
6.2
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.8
Debt to Equity
-26.8
Book Value
$--
EPS
$-1.1
Face value
--
Shares outstanding
12,103,764
CFO
$-171.06 Mln
EBITDA
$-192.10 Mln
Net Profit
$-222.47 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Evogene - ADR
| -31.4 | -7.8 | -28.8 | -35.5 | -49.5 | -55.9 | -36.8 |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Evogene - ADR
| -41.2 | 20.0 | -57.3 | -65.1 | 209.2 | -23.2 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Evogene - ADR
|
0.8 | 9.5 | 3.9 | -8.5 | -318.9 | 1107 | -- | 6.2 |
| 0.4 | 6.0 | 2.4 | -11.5 | -475.0 | -117.6 | -- | 1.0 | |
| 2.6 | 293.1 | 72.8 | 35.3 | 0.0 | 44.8 | 8.2 | 2.7 | |
| 0.8 | 214.2 | 0.0 | 1,235.5 | -- | 126.2 | 0 | 0.1 | |
| 0.6 | 4.1 | 0.0 | -10.3 | -- | -64.2 | -- | 0.3 | |
| 71.4 | 242.8 | 19.4 | -6.1 | -30.2 | -23.7 | -- | 10.6 | |
| 23.4 | 1,173.7 | 109.8 | -153.5 | -125.8 | 268.6 | -- | 19.3 |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company... engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel. Read more
CEO & President
Mr. Ofer Haviv CPA
CEO & President
Mr. Ofer Haviv CPA
Headquarters
Rehovot
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Evogene Ltd - ADR is $0.76 (NASDAQ) as of 30-Apr-2026 11:35 EDT. Evogene Ltd - ADR has given a return of -49.49% in the last 3 years.
Since, TTM earnings of Evogene Ltd - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.04
|
-107.32
|
|
2024
|
-0.68
|
-7.73
|
|
2023
|
-0.18
|
0.35
|
|
2022
|
-0.11
|
0.10
|
|
2021
|
-0.24
|
0.12
|
The 52-week high and low of Evogene Ltd - ADR are Rs 2.42 and Rs 0.72 as of 30-Apr-2026.
Evogene Ltd - ADR has a market capitalisation of $ 10 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Evogene Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.